Proof-of-concept, Single Center Study in Healthy Adult Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Prophylactic Activity of Single Dose DSM265 in a Controlled Human Malarial Infection Challenge Either by Direct Venous Inoculation of Plasmodium Falciparum Sporozoites or Mosquito-borne Plasmodium Falciparum
Latest Information Update: 08 Apr 2022
Price :
$35 *
At a glance
- Drugs DSM 265 (Primary)
- Indications Falciparum malaria
- Focus Proof of concept; Therapeutic Use
- 05 Dec 2017 Primary endpoint (Time interval between challenge and the first positive parasitemia) has been met as per the results published in the Journal of Infectious Diseases.
- 05 Dec 2017 Results published in the Journal of Infectious Diseases
- 13 Jun 2017 Status changed from active, no longer recruiting to completed.